Wobble Admin

Our latest data demonstrates a limit of detection more than an order of magnitude better than the current industry benchmark, while maintaining 100% molecular specificity at that level of sensitivity

This research demonstrates the potential of liquid biopsy to enable more precise, non-invasive treatment selection, helping match patients to the most effective therapies while reducing reliance on invasive tissue biopsies.

Wobble Genomics, a biotechnology company focused on improving cancer outcomes through better diagnosis and therapy selection, presents new data at the 2025 San Antonio Breast Cancer Symposium (SABCS), (December 9-12), in San Antonio, Texas. The data demonstrates the ability to accurately detect HER2 expression in breast cancer, both in solid tumour biopsies and blood samples.

This poster highlights Wobble Genomics’ long-read RNA sequencing platform for precise profiling of HER2 expression in breast cancer. By capturing full-length RNA transcripts, the approach enables isoform-level resolution, revealing detailed expression patterns that correlate strongly with standard IHC classifications in tumour tissue. Importantly, the study also demonstrates the potential to assess HER2 status non-invasively from blood samples, addressing a key unmet clinical need. The results show improved diagnostic accuracy and deeper insight into transcript diversity, supporting more informed patient stratification and treatment selection for HER2-targeted therapies.

This poster presents the development and analytical validation of a novel long-read RNA sequencing platform designed to detect low-abundance cancer transcripts directly from whole blood. By overcoming key limitations of traditional short-read approaches, the technology enables sensitive, full-length profiling of both short and long RNA species, even within complex biological backgrounds. The study demonstrates strong performance in detection sensitivity, precision, and transcript coverage, while also highlighting the platform’s ability to uncover clinically relevant isoforms in important cancer genes such as HER2 and TROP2. Collectively, these advances position the platform as a powerful tool for liquid biopsy applications, supporting improved cancer diagnostics, treatment monitoring, and precision medicine development.

Wobble Genomics presents a highly sensitive long-read transcriptomics platform for non-invasive profiling of breast cancer from blood. Leveraging its proprietary Level-Up technology, the platform enables comprehensive detection of cancer-specific RNA isoforms, including clinically relevant HER2 variants, with strong concordance to tumour status. The study demonstrates the potential of liquid biopsy to refine patient stratification, expand eligibility for targeted therapies, and monitor treatment response over time—offering a powerful new approach to precision oncology.

Edinburgh, UK, 6th May, 2025 – Wobble Genomics, a biotechnology company working to improve outcomes in cancer through better diagnosis and therapy selection, via a novel ultra-sensitive cell-free RNA (cfRNA) liquid biopsy diagnostic platform, today announced the appointment of Dr. Dietrich Stephan as Chairman of the Board. Dr. Stephan brings a track record in scaling